EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head

Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?

Detalles Bibliográficos
Autores principales: Clark, Jennifer, Cools, Jan, Gilliland, D. Gary
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2005
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549608/
https://www.ncbi.nlm.nih.gov/pubmed/15736989
http://dx.doi.org/10.1371/journal.pmed.0020075
Descripción
Sumario:Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?

Ejemplares similares